Released Nov 12, 2026, after the close
10-Q filed Nov 12, 2026, 43 days after period end · 0001193125-26-458680
What the release said
Revenue was $9.1 million for the quarter ended September 30, 2026, compared with $9.7 million a year earlier, and total R&D and G&A expenses were $31.0 million, compared with $48.6 million.¶1¶2
Cash, cash equivalents and marketable securities were $142.2 million as of September 30, 2026, compared with $164.3 million as of June 30, 2026, with runway expected into the first half of 2028.¶3
A second Astellas dual-payload program began dosing patients, resulting in a $10 million milestone payment received by Sutro in October 2026.¶4
STRO-006 dosed its first patient in a Phase 1 study in October 2026, with an initial Phase 1 data update anticipated in the second half of 2027.¶5
- Cash, cash equivalents and marketable securities
- $142.2 million As of September 30, 2026, compared to $164.3 million as of June 30, 2026¶3
- Revenue
- $9.1 million Quarter ended September 30, 2026, compared to $9.7 million for quarter ended September 30, 2025¶1
- Total R&D and G&A expenses
- $31.0 million Quarter ended September 30, 2026, compared to $48.6 million for quarter ended September 30, 2025¶2
- Astellas milestone payment
- $10 million Received by Sutro in October 2026 after second Astellas program began dosing patients¶4
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $9.10M | $9.69M | $8.52M | $16.92M |
| Net Income | -$31.49M | -$56.86M | -$48.79M | -$49.28M |
| EPS Diluted | -$1.90 | -$6.66 | -$0.59 | -$0.81 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR